• Dongwha Pharm plans tighter enforcement of fair-trade compliance violations in the fourth quarter of 2026.
• Third-quarter compliance monitoring covered 1,222 cases; two cases resulted in internal sanctions.
• Planned controls include stronger corporate-card monitoring, on-site inspections and checks on meetings with public officials.
• Preparations will begin for the 2027 compliance program rating assessment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dongwha Pharm Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261104800592), on November 04, 2026, and is solely responsible for the information contained therein.